|
1. Biologie
|
|
|
|
|
2. Etiologie
|
|
|
|
2.5 Etiologie - Gènes
|
|
|
|
2.6 Etiologie - Environnement
|
|
|
|
IARC's Glyphosate-gate Scandal [Forbes]
|
|
|
|
|
|
The
recent revelations regarding IARC’s glyphosate assessment throw these
issues into stark relief. Scientists and agencies need to be
transparent. It’s not acceptable for an agency to argue that “we are
impartial authorities, trust us.” Rather, we should follow the rule,
“Trust but verify” – or rather, “Distrust but verify.”
|
|
|
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
Are e-cigarettes ‘safer’ than regular cigarettes? [UNC]
|
|
|
|
|
|
“Comparing
the harm of e-cigarettes with cigarettes is a little like comparing
apples to oranges,” Kesimer said. “Our data shows that e-cigarettes have
a signature of harm in the lung that is both similar to what we see in
cigarette smokers and unique in other ways. This research challenges the
concept that switching to e-cigarettes is a healthier alternative.”
|
|
|
|
|
|
|
|
3.4.1 Chimioprévention - aspirine
|
|
|
|
3.6 Prévention - Activité physique
|
|
|
|
5.12 Immunothérapies
|
|
|
Improving immuno-oncology with electronics-inspired gene 'circuits' [FierceBiotech]
|
|
|
|
|
|
The
new approach—a gene circuit encoded in DNA—is inspired by a simple
concept used in electronics known as "AND gates." The idea is that only
when two inputs are present will the system be switched on and yield an
output. To translate it into oncology: The therapy will only be
activated when two cancer-specific biomarkers are detected.
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
Agenus creates New Cell Therapy subsidiary named AgenTus Therapeutics [Agenus]
|
|
|
|
|
|
AgenTus
will employ naturally-derived and engineered receptors, specifically T
Cell Receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to
supercharge human immune effector cells to seek and destroy cancer.
AgenTus will advance adoptive cell therapy formats which would enable
off-the-shelf living drugs.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.5 ASCO
|
|
|
|
|
Resilience Intervention Improves Well-Being in Young Patients With Cancer [ASCO]
|
|
|
|
|
|
In
this clinical trial, 100 English-speaking patients ages 12 to 25 years
who were diagnosed with new or newly recurrent cancer were randomly
assigned to receive PRISM or usual psychosocial care. The intervention
was delivered in four 30-minute to hour-long one-on-one sessions with a
trained research associate, followed by a family meeting.
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
6.10 Politiques
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.4 Médico-éco
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.8 Communication
|
|
|
|
6.9 Controverses
|
|
|
|